Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2015-000251-24-ES
EUCTR2015-000251-24-ES
Active, not recruiting
Phase 1

Impact of extremely early antiretroviral therapy to reduce VIral REservoir and induce functional CURE of HIV-1 infection. A pilot comparative study.

Fundacio Privada Clinic per a la Recerca Biomedica0 sites15 target enrollmentJune 15, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHIV-1 infectionTherapeutic area: Diseases [C] - Virus Diseases [C02]
DrugsVIREAD 245 mg COMPRIMIDOS CON CUBIERTA PELICULAREMTRIVA 200 mg cápsulasTIVICAY 50mg comprimidos recubiertos con película.ZIAGEN 300 mg comprimidos recubiertos con películaEPIVIR 300 mg comprimidos recubiertos con películaPREZISTA 800 mg comprimidos recubiertos con películaNORVIR 100 mg comprimidos recubiertos con películaCELSENTRI 150 mg comprimidos recubiertos con película

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
HIV-1 infection
Sponsor
Fundacio Privada Clinic per a la Recerca Biomedica
Enrollment
15
Status
Active, not recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 15, 2015
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
Fundacio Privada Clinic per a la Recerca Biomedica

Eligibility Criteria

Inclusion Criteria

  • •a. MSM (Men who have sex with men)
  • •b. Male?s between18 and 65 years old
  • •c. Less than 100 days of infection
  • •d. Patient stage Fiebig I to V
  • •e. Negative or Incomplete WB with negative p31 band
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 15
  • •F.1\.3 Elderly (\>\=65 years) no

Exclusion Criteria

  • •a. P31 positive band in WB
  • •b. Positive Delta32 CCR5 mutation, HLA\-B5701 or HLA\-B27 (´late? exclusion criteria)
  • •c. Active oncological disease
  • •d. Active HCV infection

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Immediate versus deferred anti-HIV-therapy in patients presenting acute AIDS-defining events.Patients in late stage of HIV-infection, treatment naive or without ART for the last 6 month with an acute AIDS-defining illness, namely PCP or TE.MedDRA version: 18.0Level: LLTClassification code 10001509Term: AIDSSystem Organ Class: 100000004862Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
EUCTR2010-022413-26-DEniversity Medical Center Hamburg-Eppendorf
Completed
Phase 2
Early ART to Limit Infection and Establishment of ReservoirHIV-1 Infection
NCT02859558Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections195
Unknown
Phase 3
Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 InfectionHIV Infections
NCT02588820David Garcia Cinca15
Completed
Not Applicable
Impact of highly active anti-retroviral therapy (HAART) during pregnancy and breastfeeding on mother-to-child transmission (MTCT) and mother's healthHuman immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)Infections and InfestationsHuman immunodeficiency virus (HIV)
ISRCTN71468401World Health Organization (WHO) (Switzerland)2,400
Recruiting
Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV RemissionHIV Infection
NCT02140255National Institute of Allergy and Infectious Diseases (NIAID)1,120